Clinical Trials Related to Chronic Lymphocytic Leukemia

Related studies linked through entity extraction aliases.

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Status: RECRUITING
Phase: PHASE1

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

Status: COMPLETED
Phase: N/A

Study of SGR-1505 in Mature B-Cell Neoplasms

Status: RECRUITING
Phase: PHASE1

Cardiotoxicities in Patients Receiving BTKi

Status: WITHDRAWN
Phase: N/A

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Status: RECRUITING
Phase: PHASE1

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL

Status: WITHDRAWN
Phase: PHASE2

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

National Acalabrutinib Observational Study

Status: ACTIVE_NOT_RECRUITING
Phase: N/A

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Status: RECRUITING
Phase: PHASE2

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Status: UNKNOWN
Phase: PHASE1

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Status: TERMINATED
Phase: PHASE1/PHASE2

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Status: SUSPENDED
Phase: PHASE1

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status: RECRUITING
Phase: PHASE2

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Status: RECRUITING
Phase: N/A

Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia

Status: NOT_YET_RECRUITING
Phase: N/A

Ibrutinib Adapted to Response in Patients With CLL

Status: NOT_YET_RECRUITING
Phase: N/A